Abstract
Background: During the last few years, Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has entered the national comprehensive cancer network guidelines as a new protocol for improving patients’ outcomes. However, there is no consensus on its long-term efficiency, and it still is under debate. Objectives: This study aims to evaluate the effectiveness of Cytoreductive Surgery Plus hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer in Iran. Method: Thirty patients with Stage IIIc and IV advanced ovarian cancer underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy at Jam Hospital with a fixed surgical team in Tehran, Iran, from 2019 to 2021. Fourteen patients were new cases, and sixteen of them were recurrent cases. At the end of cytoreductive surgery, by using a hyperthermic intraperitoneal chemotherapy device, Cisplatin was circulated in the peritoneal cavity for 90 minutes at a dose of 80-100 mg/ m2 at 43°C. Results: Among 30 patients with 54.97±10.74 years of mean age, the mean overall survival was 564.967 days, and 2-year survival rates were 66.7%. According to Fisher's exact test, there was a statistically significant relationship between disease-free after surgery and mortality rate (p=0.00). However, there was no statistically significant relationship between recurrence after surgery and mortality rate (p=0.093). Conclusion: Based on these findings, cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy had a survival rate of 66.7% within two years in advanced ovarian cancer patients. However, to achieve better results, careful selection of patients and complete cytoreductive surgery should be performed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
